TGRNF Stock Chart & Stats
$0.49
$0.00(0.00%)
At close: 4:00 PM EDT
$0.49
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.49 - $0.73
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$574.95M
Enterprise Value$1.17B
Total Cash (Recent Filing)$4.84B
Total Debt (Recent Filing)$2.17B
Price to Earnings (P/E)9.9
Beta0.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.33%
Share Statistics
EPS (TTM)0.30
Shares Outstanding628,704,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.69
Price to Sales (P/S)0.78
P/FCF Ratio3.51
Enterprise Value/Market Cap2.04
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.48
Enterprise Value/Ebitda1.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)$888.07M
Bulls Say, Bears Say
Bulls Say
Improving Balance Sheet LeverageModerate and declining leverage plus multi-year equity growth strengthen financial flexibility. This durable improvement reduces solvency risk, supports funding for capex or working-capital needs, and gives management room to navigate cyclical downturns without forced asset sales.
Strong 2025 Cash-flow ReboundA material recovery in operating and free cash flow demonstrates the company's ability to convert earnings to cash when operations normalize. Sustained cash generation supports reinvestment, dividend capacity and debt reduction, improving long-term strategic optionality.
Established TCM Brand And ChannelsA long-standing, recognized brand and an established retail/distribution footprint create durable competitive advantages in consumer trust, shelf access and channel relationships. This supports repeat sales, pricing power in core product lines, and barriers to new entrants.
Bears Say
Sustained Revenue DeclineA meaningful year-over-year revenue contraction signals weakening demand or market-share loss in core categories. Persistent top-line declines impair scale economics, limit reinvestment capacity, and make it harder to absorb fixed costs, increasing execution risk over months.
Margin Compression And Lower ProfitabilityEroding gross and net margins reduce sustainable earnings power and ROE, constraining retained earnings for growth. If cost pressures or product-mix shifts persist, margin recovery will be difficult, limiting the firm's ability to fund strategic initiatives without higher leverage.
Volatile Cash Generation / Working-capital SwingsLarge year-to-year swings in operating and free cash flow point to inconsistent working-capital management or volatile demand. This volatility undermines planning confidence, raises funding risk in downturns, and weakens the reliability of dividends and capital-allocation plans.
Tong Ren Tang Technologies Co News
TGRNF FAQ
What was Tong Ren Tang Technologies Co Ltd Class H’s price range in the past 12 months?
Tong Ren Tang Technologies Co Ltd Class H lowest stock price was $0.49 and its highest was $0.73 in the past 12 months.
What is Tong Ren Tang Technologies Co Ltd Class H’s market cap?
Tong Ren Tang Technologies Co Ltd Class H’s market cap is $574.95M.
When is Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date?
Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date is Aug 20, 2026 which is in 12 days.
How were Tong Ren Tang Technologies Co Ltd Class H’s earnings last quarter?
Tong Ren Tang Technologies Co Ltd Class H released its earnings results on Mar 27, 2026. The company reported $0.006 earnings per share for the quarter, beating the consensus estimate of N/A by $0.006.
Is Tong Ren Tang Technologies Co Ltd Class H overvalued?
According to Wall Street analysts Tong Ren Tang Technologies Co Ltd Class H’s price is currently Overvalued.
Does Tong Ren Tang Technologies Co Ltd Class H pay dividends?
Tong Ren Tang Technologies Co Ltd Class H pays a Annually dividend of $0.026 which represents an annual dividend yield of 5.33%. See more information on Tong Ren Tang Technologies Co Ltd Class H dividends here
What is Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate?
Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tong Ren Tang Technologies Co Ltd Class H have?
Tong Ren Tang Technologies Co Ltd Class H has 628,704,000 shares outstanding.
What happened to Tong Ren Tang Technologies Co Ltd Class H’s price movement after its last earnings report?
Tong Ren Tang Technologies Co Ltd Class H reported an EPS of $0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.202%.
Which hedge fund is a major shareholder of Tong Ren Tang Technologies Co Ltd Class H?
Currently, no hedge funds are holding shares in TGRNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tong Ren Tang Technologies Co Ltd Class H
Tong Ren Tang Technologies Co. Ltd., a company founded in 1669 and based in Beijing, People's Republic of China, maintains extensive operations across Mainland China and Hong Kong. Its primary activities center on the manufacturing and sale of traditional Chinese medicine products. The company's involvement is comprehensive, extending to the cultivation, sourcing, and distribution of Chinese medicinal raw materials. Beyond its core offerings, Tong Ren Tang diversifies its product portfolio with items such as ointments, tea beverages, and specialized foot care solutions. The enterprise is also active in the technological advancement and commercialization of biological products, alongside Western pharmaceuticals, cosmetics, and general healthcare goods. Its distribution network includes both wholesale and retail channels for Chinese medicines and health-related products. Furthermore, Tong Ren Tang provides a broad spectrum of services, including medical research and development, Chinese medical consultation and treatment, advertising, internal and external surgical procedures, medical examinations, and hospital management. Additionally, the company engages in the processing of biochemical products, plant extraction, and the production of various food and daily chemical items.
Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co
―
China Traditional Chinese Medicine Holdings Co
―
CSPC Pharmaceutical Group
―
Wai Yuen Tong Medicine Holdings Limited
―
Pak Fah Yeow International Limited
―
Ownership Overview
―
Insiders
4.65% Mutual Funds
― Other Institutional Investors
90.30% Public Companies and
Individual Investors